PDF(Pubmed)
Abstract：
This review provides unique insights to the scientific scope and clinical visions of the inventors and pioneers of the SoftVue breast tomographic ultrasound (BTUS). Their >20-year collaboration produced extensive basic research and technology developments, culminating in SoftVue, which recently received the Food and Drug Administration\'s approval as an adjunct to breast cancer screening in women with dense breasts. SoftVue\'s multi-center trial confirmed the diagnostic goals of the tissue characterization and localization of quantitative acoustic tissue differences in 2D and 3D coronal image sequences. SoftVue mass characterizations are also reviewed within the standard cancer risk categories of the Breast Imaging Reporting and Data System. As a quantitative diagnostic modality, SoftVue can also function as a cost-effective platform for artificial intelligence-assisted breast cancer identification. Finally, SoftVue\'s quantitative acoustic maps facilitate noninvasive temperature monitoring and a unique form of time-reversed, focused US in a single theranostic device that actually focuses acoustic energy better within the highly scattering breast tissues, allowing for localized hyperthermia, drug delivery, and/or ablation. Women also prefer the comfort of SoftVue over mammograms and will continue to seek out less-invasive breast care, from diagnosis to treatment.
摘要：
这篇综述为SoftVue乳腺断层超声（BTUS）的发明者和先驱的科学范围和临床视野提供了独特的见解。他们超过20年的合作产生了广泛的基础研究和技术发展，最终在SoftVue，该机构最近获得了食品和药物管理局的批准，作为乳房致密女性乳腺癌筛查的辅助手段。SoftVue的多中心试验证实了二维和三维冠状图像序列中定量声学组织差异的组织表征和定位的诊断目标。SoftVue质量特征也在乳腺成像报告和数据系统的标准癌症风险类别中进行了审查。作为一种定量诊断方式，SoftVue还可以作为人工智能辅助乳腺癌识别的具有成本效益的平台。最后,SoftVue的定量声学图有助于无创温度监测和独特的时间反转形式，将美国集中在一个单一的治疗装置中，实际上将声能更好地集中在高度散射的乳房组织中，允许局部热疗，药物输送,和/或消融。女性也更喜欢SoftVue的舒适性，而不是乳房X光检查，并将继续寻求侵入性较小的乳房护理，从诊断到治疗。
